To read the full story, subscribe or sign in.

AKCEA-TTR-LRx begins phase III trial for polyneuropathy caused by hATTR amyloidosis

Nov. 25, 2019

No Comments

BioWorld Science Endocrine/metabolic

Today's news in brief

BioWorld

BioWorld briefs for Nov. 29, 2023.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for November, 29 2023.

Aurinia Therapeutics’ AUR-300 proven useful in systemic sclerosis

BioWorld Science

Aurinia Pharmaceuticals Inc. has investigated their CD206 ligand AUR-300 as a novel therapeutic agent for systemic sclerosis treatment.

Historic MHRA exa-cel win bagged, Crispr/Vertex await FDA nod

BioWorld

With a landmark U.K. approval in hand for Casgevy (exagamglogene autotemcel [exa-cel]) to treat sickle cell disease and transfusion-dependent beta thalassemia,...

Astrazeneca’s AKT inhibitor is approved in breast cancer

BioWorld

Along with Enhertu, Astrazeneca plc now has another breast cancer treatment in its portfolio and it may also become a blockbuster. Truqap (capivasertib), combined...

Upgrade your daily dose of biopharma and medtech news

AKCEA-TTR-LRx begins phase III trial for polyneuropathy caused by hATTR amyloidosis